跳转至内容
Merck
CN

UHPLC/MS Analysis of Flakka (α-PVP) and α-Pyrrolidinobutiophenone in Synthetic Urine on Ascentis® Express HILIC 2.7 μm

UHPLC/MS Analysis of Flakka (α-PVP) and α-Pyrrolidinobutiophenone in Synthetic Urine on Ascentis® Express HILIC 2.7 μm application for UHPLC

材料

相关产品

产品编号
说明
价格

Ascentis® Express HILIC, 2.7 μm HPLC色谱柱

2.7 μm particle size, L × I.D. 5 cm × 2.1 mm

αα-盐酸吡咯烷基苯戊酮 盐酸盐 溶液

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

CONDITIONS

column

Ascentis Express HILIC, 5 cm x 2.1 mm I.D., 2.7 μm particles (53934-U)

mobile phase

5 mM ammonium formate in 95:5, acetonitrile:water

flow rate

0.5 mL/min

pressure

3275 psi (226 bar)

column temp.

35 °C ambient

detector

MS ESI+, MRM, 218.12 > 90.98, 232.13 > 91.04 m/z

injection

2 μL

sample

as prepared

说明

分析说明

The simple extraction from urine and rapid separation of the street drug Flakka (α-PVP) and a related compound is shown here on an Ascentis Express HILIC column in HILIC mode. Highest grade UHPLC solvents were used to supply low background interference and low particulate contaminants for robust, trouble-free operation. Cerilliant CRMs provided reliable identification and quantification.

其他说明

matrix: 100 μL of horse plasma spiked with 200 ng/mL of each analytediluant:  900 μL acetonitrilevortex: 30 seccentrifuge:  10,000 rpm for 1 minfilter:  0.45 μm (Z227544)

法律信息

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany